Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped up prior to trading on Monday . The stock had previously closed at $57.50, but opened at $61.77. Zealand Pharma A/S shares last traded at $61.00, with a volume of 1,630 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ZLDPF shares. Wells Fargo & Company raised Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. Barclays raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Monday, July 7th. BNP Paribas raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, July 1st. Finally, Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Zealand Pharma A/S Stock Up 6.1%

The firm’s 50 day moving average is $57.53 and its 200-day moving average is $70.34. The firm has a market cap of $4.33 billion, a PE ratio of 4.28 and a beta of 0.71. The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing analysts’ consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%.The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $9.18 billion. As a group, equities research analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.